Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>Events>This Event
  Events - July 2014

Biochemical Assays for Screening Workshop

09 Jul 2014 - 11 Jul 2014 - Hamburg, Germany

Bookmark and Share

Taking place over three days at the European ScreeningPort facility in Hamburg, the workshop will offer attendees the chance to participate in practical sessions using the latest technology available from the top screening equipment / reagent vendors in the pharmaceutical industry.

This is a must-attend event for anyone in the drug discovery industry to learn about screening technologies and discover what they can do for your company or laboratory.

Who should attend

• Scientists at all levels (undergraduates, postgraduates and laboratory based scientists within academic and industrial research organisations) who are engaged in early stage drug discovery and have an interest in the development, validation and utilisation of biochemical assays for screening against small molecule libraries.

• The course will include a series of lectures describing the screening compatible biochemical assays for use in drug discovery.

• The majority of the course will be laboratory based in which assays for targets that are currently actively being pursued for drug discovery purposes (kinases, histone deacetylases and proteases) will be developed, validated and screened against a small molecule library (known drugs). Selected Hit compounds will be evaluated in suitable Secondary assays.

Expected outcomes from the workshop

It is envisaged that upon completion of the course, attendees will have gained an insight into the key parameters to be considered when developing biochemical assays and performing small molecule screening, data analysis and validation of Hits in suitable Secondary assays.

Agenda Topics

•    Km Determination for Substrates
•    Aspects of Adaption of Assays for Screening of a Small Molecule Library (Known Drugs)
•    Choice of Biochemical Assay Development Projects: Kinase, Protease or Histone Deacetylase
•    Data Analysis and Classifying Compounds as Hits
•    IC50 Determination for Inhibitor, Signal Stability, Choice of Liquid Handling and Z’
•    Interferers
•    Kinetic Characterisation of Enzymes
•    Validation of Hits Selected from Screening Campaigns

Further information
Scientific News
Lucentis Effective for Proliferative Diabetic Retinopathy
NIH-funded clinical trial marks first major advance in therapy in 40 years.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Gene Therapy Staves Off Blindness from Retinitis Pigmentosa in Canine Model
NIH-funded study suggests therapeutic window may extend to later-stage disease.
Treatment for Rare Bleeding Disorder is Effective
Researchers in Manchester have demonstrated for the first time the relative safety and effectiveness of treatment, eltrombopag, in children with persistent or chronic immune thrombocytopenia (ITP), as part of an international duo of studies.
HIV Vaccine Human Trials Begin
Baltimore-based Institute has begun enrolling volunteers for initial phase 1 clinical trials.
New Therapy Reduces Symptoms of Inherited Enzyme Deficiency
A phase three clinical trial of a new enzyme replacement medication, sebelipase alfa, showed a reduction in multiple disease-related symptoms in children and adults with lysosomal acid lipase deficiency, an inherited enzyme deficiency that can result in scarring of the liver and high cholesterol.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos